Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
出版年份 2022 全文链接
标题
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-12-08
DOI
10.3389/fonc.2022.977664
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
- (2020) Atefeh Arab et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model
- (2020) Xiulan Lai et al. PLoS One
- PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
- (2020) Zhengping Hu et al. PLoS One
- Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
- (2020) Regina Padmanabhan et al. Cancers
- Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer
- (2020) Christian Bailly et al. BIOCHEMICAL PHARMACOLOGY
- Targeting HER2 expression in cancer: New drugs and new indications
- (2020) Semir Vranic et al. Bosnian Journal of Basic Medical Sciences
- Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019)
- (2020) Qiaohong Geng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice
- (2020) Cenk Serhan Özverel et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
- (2020) Yuka Kuroiwa et al. Cancers
- Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
- (2020) Helena Earl et al. HEALTH TECHNOLOGY ASSESSMENT
- Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells
- (2020) Ayesha Jabeen et al. MOLECULES
- Regulatory mechanisms and clinical significance of vimentin in breast cancer
- (2020) Zhilong Chen et al. BIOMEDICINE & PHARMACOTHERAPY
- Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
- (2019) Gaia Griguolo et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Development of the Inhibitors that Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
- (2019) Guzik et al. MOLECULES
- Intermediate Filaments as Effectors of Cancer Development and Metastasis: A Focus on Keratins, Vimentin, and Nestin
- (2019) Pooja Sharma et al. Cells
- Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
- (2019) Claudio Vernieri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
- (2019) In-Wha Kim et al. Frontiers in Oncology
- Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
- (2019) Sandra Martinez-Morilla et al. LABORATORY INVESTIGATION
- A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2‐Positive Metastatic Breast Cancer (CCTG IND.229)
- (2019) Stephen Chia et al. ONCOLOGIST
- Systems biology based drug repositioning for development of cancer therapy
- (2019) Beste Turanli et al. SEMINARS IN CANCER BIOLOGY
- Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
- (2019) Deepak Mittal et al. OncoImmunology
- Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse
- (2019) Tadashi ASHIZAWA et al. BIOMEDICAL RESEARCH-TOKYO
- Mathematical Modeling, Analysis, and Simulation of Tumor Dynamics with Drug Interventions
- (2019) Pranav Unni et al. Computational and Mathematical Methods in Medicine
- Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
- (2019) E. Krasniqi et al. Journal of Hematology & Oncology
- Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer
- (2019) Bum-Sup Jang et al. RADIOTHERAPY AND ONCOLOGY
- Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer
- (2019) Rui Zhang et al. Small
- Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer
- (2019) Angela M. Jarrett et al. Scientific Reports
- Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
- (2019) Aravindhan Ganesan et al. Scientific Reports
- Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
- (2019) Sasagu Kurozumi et al. Scientific Reports
- Towards personalized treatment for early stage HER2-positive breast cancer
- (2019) Kristina Goutsouliak et al. Nature Reviews Clinical Oncology
- PD-L1 status in breast cancer: Current view and perspectives
- (2019) Semir Vranic et al. SEMINARS IN CANCER BIOLOGY
- Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
- (2018) Markella Konstantinidou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
- (2018) N.A. Nixon et al. EUROPEAN JOURNAL OF CANCER
- Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
- (2018) Eva-Maria Rom-Jurek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
- (2018) Marcelo Sobral-Leite et al. OncoImmunology
- HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
- (2018) Tiziana Triulzi et al. OncoImmunology
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment
- (2017) A B Nagaraj et al. ONCOGENE
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
- (2017) Stephen J. Luen et al. PATHOLOGY
- Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model
- (2017) Xiulan Lai et al. PLoS One
- Current challenges in HER2-positive breast cancer
- (2016) Fabio Puglisi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- A Comparison and Catalog of Intrinsic Tumor Growth Models
- (2014) E. A. Sarapata et al. BULLETIN OF MATHEMATICAL BIOLOGY
- Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth
- (2014) Sébastien Benzekry et al. PLoS Computational Biology
- Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases
- (2013) H. Zhao et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search